利拉鲁肽
大肠杆菌
融合蛋白
蛋白酶
重组DNA
化学
包涵体
肽
蛋白质工程
融合
靶蛋白
生物化学
产量(工程)
计算生物学
串联质量标签
细胞生物学
蛋白质降解
肽序列
劈理(地质)
表达式向量
蛋白质表达
蛋白质水解
氨基酸
蛋白酵素
血浆蛋白结合
生物
蛋白质纯化
作者
Pavan Reddy Regatti,Firdose Syed,Ramesh V. Matur,Kirtimaan Syal
出处
期刊:Protein Science
[Wiley]
日期:2026-05-13
卷期号:35 (6): e70594-e70594
被引量:1
摘要
Glucagon-like peptide-1 (GLP-1), a 31-amino acid incretin hormone, is widely used in the treatment of type 2 diabetes mellitus due to its glucose-dependent insulinotropic activity. However, its small size makes it highly prone to proteolytic degradation in microbial expression systems such as Escherichia coli, leading to reduced manufacturing yield. While fusion to cleavable protein tags can improve peptide stability during purification, excessively large tags often compromise the overall yield, especially when the target peptide is smaller than the fusion partner. To overcome this limitation, we have engineered 11 cleavable fusion tag constructs (LP1-LP11) for recombinant expression of Arg34-GLP-1(7-37) (liraglutide precursor) in E. coli. The 11 constructs differed only in the tags. The expression vector contained a T7 leader sequence, affinity tags (6×His/6×Arg), inclusion body tags (11-125 amino acids), and TEV protease cleavage sites. Among the 11 tags, LP8 with a compact 4.0 kDa tag achieved the highest expression, yielding 133 mg/L of fusion protein and a calculated liraglutide precursor yield of 60 mg/L based on mass fraction (45% of fusion mass), with an actual recovered yield of 14.6 mg/L after RP-HPLC purification, largely due to efficient inclusion body formation (>95% insolubility) and enhanced translational initiation driven by the T7 leader sequence. The purified peptide's identity and sequence integrity were confirmed by LC/MS analysis. The primary advantage of this approach is mass fraction optimization which focuses on minimizing fusion-tag mass to maximize yield relative to the tag size without compromising inclusion-body formation thereby providing a scalable and economical approach for GLP-1 analogs and potentially other peptide-based biopharmaceuticals.
科研通智能强力驱动
Strongly Powered by AbleSci AI